Safety and Efficacy of Mistletoe extract (Viscum album)

Iscador(R) P in Equine Sarcoid by Clottu, Ophélie et al.
Background
Equine Sarcoid (ES), a semi malignant skin tumour, is the most common neoplasia of horses (Marti et al.1993). There is no generally effective single treatment 
existing and the recurrence rate is high (Martens et al.2001). Furthermore as a treatment obstacle, Sarcoids tend to occur as multi-focal tumours or can be found in 
critical locations (peri-ocular) where success of surgical interventions is very limited (Carstanjen et al.1997). Due to encouraging results in human medicine and 
small animals practice after adjuvant cancer treatment by mistletoe extracts (Biegel et al.2007) the viscum therapy could hypothetically fill a therapy gap for equine 
tumour diseases as well. Hence, goal of this clinical trial was to evaluate the safety and efficacy of Viscum album pini (Iscador® P) as a primary therapy of Equine 
Sarcoid in the context of a prospective, randomized, controlled, double-blind study.
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Subjects and Methods
53 horses with histologically confirmed diagnosis Equine Sarcoid were randomly assigned as Iscador (I; n=32) or Control group (C; n=21). There are 23 mares, 25 
geldings and 5 stallions ranged in age from 3 to 17 years with an average of 7.2 years. The horses received escalating dosages of Iscador® P starting at 0.1mg up to 
20 mg extract per 1 ml dose or physiological NaCl solution 3 times a week over 105 days sub-cutanously into the pectoral region. The number, localization and 
morphology of the ES were observed and documented over 12 months. As target variable the positive outcome rate (PO rate) was calculated representing the 
patients status at the end of the investigation.
Results
2. Overall outcome:
In the Iscador Group 13 horses (41%) showed an improvement (at least 
50% tumour remission). Of these cases a number of 9 patients showed 
complete cure (28%). In the Control Group only 3 cases (14%; all with 
complete cure) were classified as improved (p<0.05).  
Discussion & Conclusions
Iscador® P extract (viscum album pini) represents a safe and efficient therapy alternative in Equine Sarcoids, particularly in cases of multi-focal character. In 
tumours grown in problematic localizations a therapy attempt with viscum album extracts should be conducted to avoid the risk of damage the intact surrounding 
tissue, particularly in the eye area. Iscador®Pshows significantly better outcomes (cure and improvement) compared to placebo control. Younger horses and 
horses with more than 2 tumours are responding with higher PO rates than older patients and horses with 1 to 2 ES. This fact could support the control of multiple 
sarcoids which can be excised only by immense surgery expense. Further investigations to understand factors of response and non-.response have to be 
conducted in the future. Additionally, due to the good tolerance by the patients and the acceptance of long-term protocol the practicability of Iscador ®Ptherapy 
can be assumed. 
Younger horses responded more often with a positive outcome (PO) than 
older (Fig. 2a) with PO rates of 57%, 40% and 13% for horses being less 
than 5 years, 5 to 9 years and more than 9 years, respectively compared 
to PO 25%, 10% and 0% in control. A significant better therapy course 
appeared in the Iscador group for horses with >2 ES (Fig. 2b): a number 
of 12 of 25 horses (48%) showed an improvement, 9 of these a complete 
remission (36%) including ES localized at the critical areas (head and 
around the eyes) compared to 6% in the control group. 
Fig. 2a: outcomes depending on age Fig. 2b: outcomes depending on no. of ES
1. Tolerance and undesired side effects: As side effects of the 
Iscador® P injections in 5  of 32  cases a slight swelling (edema) could 
be observed which decreased spontanously within few days. 
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Iscador (n=32) Placebo (n=21)
Cure* Improvement**
Constance*** Decrease****
<5 years 5-9 years 10+ years
****Decrease: Tumour size increase by  at 
least 50%, transformation to fibroblastic typus
or new tumours
***Konstance: Tumour size changes <50%
**Improvement: Tumour size reduction by at 
least 50%
*Cure: Tumours completely disappeared; no 
recurrences
1-2 ES 3-9 ES 10-45 ES
3. Cases
a. Swiss Warmblood horse, mare, 
aged 7 (1997)
Occult, verrucous und mixed sarcoids
on  head, neck, lower abdomen, and 
inner side of hind leg (n=7)
Iscador-treatment: 04-04 to 15-07-05
b. Franches-Montagnes horse, mare 
aged 6 (1999)
Occult, verrucous and mixed sarcoids on 
head, lower abdomen and inner side of 
hind leg (n=9)
Iscador-Treatment: 03-10-05 to 15-01-06
I------------ Iscador-treatment ------------II-------------------------- Observation Time ------------------------I
before therapy               month 1              month 2        month 5                   month 10               month 12
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